Overview of Тералиджен

Quick Facts

Property	Description
Active ingredient	Alimemazine (as the tartrate salt)
Form	Oral tablets and Solution for injection
Pharmacological class	First-generation Antihistamine; Phenothiazine Derivative
Common purpose	Relief of allergic symptoms and promotion of calming/relaxation
Origin	Synthetic

What is Тералиджен (Alimemazine) and What Type of Drug is It?

Teralidzhen is the name commonly associated with a pharmaceutical product whose active ingredient is Alimemazine, a synthetic compound classified as a phenothiazine derivative. It primarily acts as a first-generation H1-antihistamine. Phenothiazine derivatives are utilized in managing certain behavioral issues related to their calming effects, illustrating a diverse pharmacological profile. This dual action provides an allergy blocker with significant central nervous system effects.

How is Тералиджен Formulated (Composition and Form)?

This medication is manufactured as a single-ingredient product where the active substance is Alimemazine, typically supplied as the tartrate salt. It is available in two main dosage forms for two different routes of administration: film-coated tablets for oral intake and a sterile solution intended for intramuscular injection. Alimemazine is classified as an anti-allergic agent. The availability of both oral and injectable options provides clinical versatility.

What is the General Therapeutic Purpose of Teralidzhen?

The general purpose of Teralidzhen is to provide simultaneous relief from allergic symptoms and emotional distress by influencing nerve signals. Its anti-histamine action helps to combat allergic reactions that manifest physically, such as persistent itching and hives. Furthermore, its inherent calming effect addresses conditions characterized by emotional tension, restlessness, or agitation. This property is recognized for helping patients achieve necessary rest when discomfort or anxiety interferes with sleep.

What side effects are possible with Тералиджен?

Official Safety Profile and Documented Adverse Reactions

The safety profile of Alimemazine (Тералиджен) is officially defined by its classification as a phenothiazine derivative and first-generation antihistamine. Regulatory documents categorize possible adverse reactions based on their frequency and the affected body system (System-Organ Class or SOC).

Commonly Documented Effects

The most frequently reported adverse reactions, classified as Common in regulatory labeling, are related to the central nervous system and include drowsiness/sedation, headache, and dizziness. These effects are often noted to be more pronounced at the beginning of treatment. Other common effects may include nasal congestion/stuffiness.

System-Organ Classification (SOC)

Adverse effects are formally grouped by the system they affect, including Nervous System Disorders, Psychiatric Disorders (e.g., agitation), Gastrointestinal Disorders (e.g., dry mouth, constipation), and Cardiac Disorders (e.g., changes to heart rhythm).

Serious Adverse Reactions

Official prescribing information documents rare but clinically significant serious reactions. These include the potential for Neuroleptic Malignant Syndrome (NMS), a severe, complex reaction, and certain cardiac arrhythmias, such as Torsade de Pointes. Other rare, serious risks include severe blood disorders like agranulocytosis and liver-related reactions such as cholestatic jaundice.

Population and Time-Related Safety Constraints

Safety documents specify constraints for particular populations. Older adults may be more sensitive to effects like orthostatic hypotension, sedation, and urinary retention. The medication is officially contraindicated for use in children under 2–3 years of age due to the risk of respiratory depression and marked sedation. The risk of Tardive Dyskinesia, a severe movement disorder, is associated with prolonged exposure. Furthermore, the use of Alimemazine is restricted in individuals with pre-existing conditions such as severe hepatic/renal dysfunction, epilepsy, Parkinson's disease, or narrow-angle glaucoma.

Overdose and Emergency Response

An overdose of Teralidzhen (Alimemazine) presents with documented severe manifestations affecting the central nervous system and cardiovascular function. Clinically observed presentations include CNS depression, ranging from profound drowsiness and somnolence to loss of consciousness and coma. Severe motor disturbances, such as extra-pyramidal dyskinesias, muscle spasms, and seizures, are also regulatory-listed outcomes.

Cardiovascular instability is a critical feature, involving hypotension, tachycardia, and a documented risk of life-threatening ventricular arrhythmias, including ventricular fibrillation and cardiac arrest. Systemic effects such as hypothermia and circulatory collapse are also officially noted.

Urgent medical attention is required immediately for any suspected overdose. The onset of severe symptoms, such as the signs of Neuroleptic Malignant Syndrome (NMS)—including high temperature and muscle rigidity—requires the medication to be discontinued at once and intensive clinical follow-up started.

The official prescribing information states there is no specific antidote known for Alimemazine overdose. Management is uniformly described as symptomatic and supportive treatment. Procedural measures may include the administration of activated charcoal and attempted gastric lavage, typically if seen within six hours of ingestion. An increased mortality risk is specifically noted when overdose occurs in combination with alcohol or other substances. Pediatric patients are noted in official sources for an increased vulnerability to severe events, including respiratory depression and seizures.

Therapeutic Uses of Тералиджен

What Тералиджен Treats: Main Uses and Benefits

The therapeutic uses of Teralidzhen (Alimemazine) span two primary clinical areas, relevant in contexts marked by increased discomfort or tension that interferes with comfort and functioning. Its use is aligned with therapeutic guidance and is applied across domains where additional symptomatic support is needed. This medication is generally used to help manage symptomatic distress from pathological anxiety, restlessness, and emotional tension often associated with neurotic and anxiety-depressive disorders. Furthermore, it is applied for the symptomatic relief of intense pruritus (itching) and the rash of urticaria (hives), and for short-term sedation in children prior to clinical procedures.

In these situations, the medication provides supportive relief that helps ease the overall symptom burden. It supports patients during episodes of heightened discomfort, whether from emotional distress or persistent itching, contributing to improved comfort and functional stability. The supportive element is commonly used when symptoms interfere with a patient’s ability to gain adequate rest. The calming effects are particularly relevant for managing sleep disturbances and night awakenings when they are consequences of anxiety or physical irritation.

Quick Fact: Relief for Dual Symptom Domains

Domain	Primary Benefit
Neurotic/Anxiety	Supports the patient during difficult episodes by easing distress; eases tension.
Allergic/Pruritus	Contributes to symptom relief for intense itching.
Sleep	Assists with functional stability when rest is disturbed.

Regulatory References

Scottish Government Prescribing Guidance on Alimemazine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Тералиджен (Alimemazine)

Official regulatory documents establish clear boundaries for Alimemazine use based on age, physiological status, and pre-existing medical conditions.

Eligibility Scope

Category	Eligibility Rule
Populations Allowed	Adults; children over 2 years of age for symptomatic relief of pruritus and urticaria.
Populations Not Recommended	Pregnant women (avoidance advised unless essential); breastfeeding mothers (discontinuation of nursing required); the elderly (use with caution and reduced dosage).
Populations Contraindicated	Children less than 2 years of age (absolute prohibition); patients with known hypersensitivity to phenothiazines or excipients.

Condition-Specific Eligibility Rules

Use is contraindicated in patients diagnosed with:

Organ Dysfunction: Severe hepatic or renal dysfunction.
Comorbidities: Epilepsy, Parkinson’s disease, Hypothyroidism, Phaeochromocytoma, Myasthenia gravis, history of narrow-angle glaucoma, and prostatic hypertrophy.

Eligibility-Related Restrictions also mandate caution for the elderly, patients with certain cardiovascular diseases, or those with a history of seizures, as documented in official prescribing information.

Resulting Eligibility Structure

Regulatory documents define eligible use primarily for adults and older children without underlying contraindicating conditions. The Contraindicated status creates an absolute exclusion for individuals with specific neurological, endocrine, or organ function disorders. Use in the elderly is officially restricted to caution and dose modification due to increased susceptibility risks, while pregnancy and lactation are labeled with advisories for avoidance or required cessation of breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Тералиджен (Alimemazine) details significant interactions classified primarily by pharmacodynamic potentiation and pharmacokinetic interference.

Drug-Drug and Pharmacodynamic Interactions

The most substantial documented interaction is the additive effect with other Central Nervous System (CNS) depressants, including anxiolytics, hypnotics, sedatives, and opiates. Co-administration intensifies the sedative effects. Furthermore, agents with anticholinergic properties, such as tricyclic antidepressants and Monoamine Oxidase Inhibitors (MAOIs), may see an enhancement of their specific effects. Co-administration with antihypertensive drugs may lead to an exaggeration of the drug's hypotensive effect, which is an important consideration. A strong restriction notes that Adrenaline (Epinephrine) is contraindicated for treating circulatory collapse in overdose.

Absorption and Timing Rules

Certain oral substances interfere with Alimemazine exposure. Antacids containing aluminum or magnesium hydroxide, along with other gastrointestinal agents, are documented to reduce the absorption of Alimemazine. To mitigate this pharmacokinetic interaction, regulatory documents advise administering Alimemazine at least two hours apart from these agents.

Substance Restrictions and Population Notes

Patients are strongly advised to avoid consumption of alcohol throughout the entire treatment period due to the risk of severe intensification of central effects. Treatment also requires the avoidance of exposure to direct sunlight due to a documented photosensitivity risk. For elderly patients, the rate of metabolism and excretion of Alimemazine is decreased, making them more susceptible to the orthostatic hypotensive effects when combined with relevant agents.

Mechanism of Action

How Тералиджен Works: Mechanism of Action

Тералиджен (Alimemazine) exerts its pharmacological action through competitive antagonism at multiple central and peripheral receptor sites. Its mechanism is defined by the non-selective blockade of key neurotransmitter systems, primarily driven by its high lipophilicity, which facilitates rapid access to the Central Nervous System (CNS).

Central Nervous System (CNS) Pathway Depression

The drug's core central effect results from the competitive blockade of histamine H1 receptors and muscarinic acetylcholine receptors (mAChR) in the brain. This antagonism interrupts signals from the histaminergic arousal pathway and reduces cholinergic transmission. The consequence of this suppression of excitatory CNS input is the induction of a physiological state characterized by decreased central arousal.

Dual Modulation of Inflammatory and Neurotransmitter Systems

Peripherally, Alimemazine blocks H1 receptors, thereby disrupting the initial stages of the inflammatory cascade and reducing histamine-mediated effects, including increased capillary permeability and the excitation of sensory nerves. Additionally, the drug engages in secondary neurotransmitter modulation through weaker antagonism of D2 dopamine and alpha1 adrenergic receptors, which influences emotional pathways and vascular tone, defining the characteristics of its broad-spectrum receptor antagonism.

Dosage and Administration Information

The administration of Alimemazine (Тералиджен) is determined by its dosage form and the patient population. The medication is primarily for oral use and is supplied as film-coated tablets (typically 10 mg) or various strengths of oral solution/syrup (e.g., 7.5 mg/5 ml or 30 mg/5 ml). An injectable solution for intramuscular administration is also available.

Official Administration Guidelines

Population & Context	Standard Labeled Dosing Regimen
Adults (Symptomatic Relief)	10 mg taken two or three times daily. In severe cases, doses up to 100 mg per day may be utilized.
Older Adults	The dose is reduced to 10 mg taken once or twice daily.
Children (Pre-anaesthesia Sedation)	A single, time-bound dose administered 1–2 hours before the operation. The maximum dose is specified as 2 mg per kg bodyweight.

The tablets and oral solutions may be taken with or without food. For the liquid formulation, appropriate dispensing tools, such as a graduated syringe, are necessary to ensure accurate volume measurement. It is specified that the recommended dose is not to be exceeded. If a dose is missed during a divided-dose schedule, the standard procedure is to skip the missed dose and take the next dose when it is due, without taking a double dose to compensate. Furthermore, the use of this medication is generally not recommended for children below 2 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Тералиджен

Evidence for Management of Emotional Distress and Anxiety

Research has explored whether the medication was studied for conditions in study populations managing Generalized Anxiety Disorder (GAD) and emotional tension in adults. Studies examining this use were often conducted during periods of increased symptom activity. These trials primarily used open-label designs, monitoring measurements of anxiety severity scores over short timeframes. Comparative evidence against other established treatments is currently lacking, and there is limited information for long-term outcomes regarding sustained management of GAD.

Evidence for Symptomatic Relief of Itching and Urticaria

Тералиджен was evaluated in research for managing intense pruritus (itching) and the episodic manifestations of urticaria (hives). This evidence base is often referred to in official documentation due to the drug's classification as a first-generation antihistamine, suggesting a history of use in conditions associated with acute episodes. However, there is a recognized absence of recent, large-scale, placebo-controlled trials specifically comparing this medication to current standards of care.

Evidence for Sleep Disturbance and Short-Term Sedation in Children

Research explored the use of the drug in pediatric populations for sleep disturbance (night waking) and its use in research examining pre-procedural sedation. Small randomized trials monitored measurements of change in waking frequency in young children. These studies are often characterized by modest sample sizes, and evidence suggests the observed effects may be transient, meaning certainty remains low regarding sustained changes.

Research Gaps, Long-Term Studies, and Special Populations

The overall evidence landscape is characterized by certain limitations. Follow-up durations for many efficacy trials were short, typically six weeks, meaning data on the durability of effects over many months are not well established. Data for older adults are often lacking, and the results primarily apply to the adult populations studied for GAD and pruritus. Overall, the evidence highlights what is known—and what is still uncertain—with certain indications requiring further, independent research to better establish the broader evidence landscape.

Key Studies & References SY ICB Shared Care Protocol: Alimemazine for patients within Sheffield Children's Hospital Tertiary Sleep Service

Frequently Asked Questions (FAQ)

Common questions about Тералиджен (FAQ)

Q: What is Teralidzhen prescribed for besides anxiety?

Official documents describe its use for conditions including anxiety, certain forms of insomnia (sleep disturbances), and symptomatic relief of pruritus (itching) and urticaria (hives). This information is consistent with its classification as a phenothiazine derivative and a first-generation antihistamine.

Q: Is it acceptable to take Teralidzhen for a long period?

Regulatory documents note that prolonged exposure to medicines in this class is associated with a specific, rare risk of Tardive Dyskinesia, a type of movement disorder. The need for monitoring the duration of treatment is part of the professional guidance.

Q: Are there restrictions on driving a car while taking Teralidzhen?

Official warnings state that the medicine can commonly cause side effects like drowsiness, dizziness, and sedation. Due to these effects, the ability to drive or operate machinery may be impaired, and regulatory warnings are issued regarding this risk.

Q: Is Teralidzhen classified as an antidepressant?

No. The regulatory classification defines Teralidzhen (Alimemazine) as a phenothiazine derivative and a first-generation antihistamine, rather than classifying it as a standard antidepressant medicine. Its primary actions are on histamine and other neurotransmitter receptors.

Q: Does Teralidzhen have a strong sleep-inducing (hypnotic) effect?

Drowsiness and sedation are explicitly listed as common adverse effects in official product information, indicating its ability to induce sleepiness. This effect is consistent with its known action as an H1 receptor antagonist in the central nervous system.

Q: Is it possible to take Teralidzhen only when necessary?

The regulatory label includes specific dosing regimens for single-dose use, such as administration before a medical procedure, in addition to maintenance schedules for ongoing symptoms. Any use must align strictly with the specific instructions provided by the prescribing professional.

Q: Is it acceptable to take Teralidzhen with common painkillers?

Co-administration with certain agents that depress the Central Nervous System (CNS), such as opioid analgesics (a type of painkiller), may result in an additive sedative effect. The combination carries a documented risk of an intensified sedative effect.

Q: Are there any dietary restrictions when taking Teralidzhen?

The medicine may be taken with or without food, as official instructions do not specify a general dietary restriction. However, regulatory documents advise administering Teralidzhen at least two hours apart from certain gastrointestinal agents, like antacids, to avoid affecting its absorption.

Q: Can Teralidzhen cause sleep disturbances?

While its primary effect is sedation, the official adverse reaction profile does include reports of agitation, restlessness, or insomnia (sleep disruption) under the Psychiatric Disorders classification. Official information indicates a potential for these paradoxical effects to occur.

Q: How long after taking Teralidzhen does it start working?

Pharmacokinetic data in official documents indicate the peak plasma concentration, where the substance reaches its highest level in the bloodstream, is typically attained within one to two hours after oral administration. This time frame indicates when the substance reaches its highest concentration in the bloodstream.

Q: Why is Teralidzhen sometimes called a "minor tranquilizer"?

This terminology is part of the medicine's historical classification based on its early use for anxiolytic (antianxiety) effects and its comparatively lower risk profile than major tranquilizers. Its formal regulatory classification remains as a phenothiazine derivative.

Q: Does Teralidzhen cause habituation or dependence?

Official regulatory warnings advise on the risk of physical or psychological dependence associated with the use of medications that exert effects on the Central Nervous System (CNS). This potential risk is noted in the special warnings section of the prescribing information.

Q: How does Teralidzhen affect body weight?

Official regulatory labels include weight gain as a potential adverse effect listed under the Metabolism and Nutrition disorders classification. This information is detailed within the full official safety profile under that section.

Q: How long does the effect of Teralidzhen last?

Regulatory documents specify the plasma elimination half-life of the active substance. This value indicates the time required for the amount of medicine in the body to be reduced by half.

Q: Is a doctor’s prescription required to purchase Teralidzhen?

Yes. Teralidzhen (Alimemazine) is classified as a Prescription-Only Medicine (POM) according to the regulatory status in most countries where it is available. It is not available for purchase without an authorized prescription.

Q: Is it safe to stop taking Teralidzhen abruptly?

Official prescribing information guides that the dose should be gradually reduced upon cessation of treatment. This procedure is generally advised to minimize the potential for rebound or withdrawal symptoms.

Q: Is it acceptable to take Teralidzhen during pregnancy?

Official documents contain warnings and restrictions for its use during pregnancy. It is often stated that the medicine is not recommended unless a qualified professional determines the benefits outweigh the potential risks.

Q: Is Teralidzhen compatible with breastfeeding?

Official documents specify that the active substance excretes into breast milk, and they contain warnings about potential risks to the breastfed infant. Use during breastfeeding is typically restricted or not recommended.

Q: Are medical tests required before starting Teralidzhen?

Due to the rare risk of severe blood disorders, regulatory labels advise that specific baseline monitoring may be necessary before initiating treatment. These tests often include monitoring of blood cell counts, and official regulatory documents advise that this is necessary.

Q: Is Teralidzhen used in psychiatry or neurology?

Yes. The medicine’s official indications (such as anxiety and sedation) and its known effects on the Central Nervous System (CNS) mean it falls within the scope of both psychiatric and neurological care.

Q: Is it necessary to gradually increase the dose of Teralidzhen?

Official dosing guidelines typically recommend gradual dose titration (slowly increasing the dose). This procedure is primarily advised to minimize the occurrence of initial side effects.

How should Тералиджен be stored and disposed of?

Official Storage and Disposal Requirements

To ensure product stability, Alimemazine (Тералиджен) must be stored within specific temperature and environmental constraints as defined by regulatory labeling.

Storage Condition	Official Regulatory Requirement
Temperature Limits	Oral solution must be stored below 25 C; tablets must not be stored above 30 C.
Light Protection	Store the medicine in the original package to protect from light.
In-Use Stability	The liquid formulation must not be used more than one month after the bottle has been opened.

All formulations must be kept strictly out of the sight and reach of children. Regarding disposal, the label prohibits discarding any unused medicine via wastewater or household waste to protect the environment. Disposal must be completed by consulting a pharmacist for instructions on safe, authorized disposal methods.

Тералиджен